While CASP8 mutation does not explain the aggressive nature of RDEB SCC, it does point to RDEB SCC being “immune hot,” which has been linked to immune checkpoint success [88] (discussed below) and could be a potential genetic target for future therapy development. Here, CASP8 is linked to recessive dystrophic epidermolysis bullosa.